Barrett Oesophagus Surveillance
On this page
Direct answer
Columnar metaplasia with intestinal metaplasia replacing the distal squamous lining — Barrett oesophagus — is the strongest recognised precursor of oesophageal adenocarcinoma, and the reason long-standing reflux earns an endoscopy. Confirmed nondysplastic Barrett is surveyed endoscopically every three to five years with protocolised four-quadrant biopsies; confirmed dysplasia shifts management to endoscopic therapy — endoscopic mucosal resection for visible lesions and radiofrequency ablation for flat dysplasia — while oesophagectomy is reserved for disease beyond the mucosa. Antireflux surgery controls symptoms but does not reliably regress metaplasia or abolish cancer risk, so surveillance continues after fundoplication.
What you must remember
- The diagnosis requires intestinal metaplasia on biopsy from a visibly abnormal segment; a columnar-looking z-line without intestinal metaplasia is not Barrett in most guidelines.
- Prague C&M classification records the circumferential (C) and maximal (M) extent of the segment in centimetres; segments of 3 cm or more are "long-segment" and carry higher progression risk than short segments.
- Progression from nondysplastic Barrett to adenocarcinoma is slow — commonly quoted around 0.1–0.5% per year — which is why surveillance rather than ablation is the default.
- Seattle protocol: four-quadrant biopsies every 2 cm along the segment (every 1 cm in dysplasia) plus targeted biopsies of any visible abnormality.
- Surveillance interval: 3–5 years for nondysplastic disease; indefinite-for-dysplasia and low-grade dysplasia shorten this, with low-grade confirmed by an expert pathologist generally offered ablation.
- Visible lesions (nodules, ulcers) are removed by endoscopic mucosal resection first — histology of the lesion then stages the field; flat dysplasia is ablated (radiofrequency ablation is standard).
- High-grade dysplasia or intramucosal carcinoma confined to the mucosa is managed endoscopically in most fit-for-endoscopy patients; submucosal invasion (sm2/sm3), uncertain margins or multifocal disease tilt towards oesophagectomy.
- Chemoprevention: high-dose proton-pump inhibitor plus aspirin showed benefit in the AspECT trial — a modern, quotable fact.
- After fundoplication, surveillance continues: the metaplastic segment, once present, is monitored regardless of symptomatic success.
Reading a report and deciding the pathway
A 54-year-old man with two decades of reflux symptoms has his first endoscopy: an irregular z-line with a 5 cm circumferential columnar segment extending 8 cm maximally — Prague C5M8 — with no nodularity. Seattle-protocol biopsies every 2 cm report intestinal metaplasia without dysplasia. He enters a surveillance programme: repeat endoscopy in three to five years, PPI therapy, weight and lifestyle counsel. The reasoning is arithmetic as much as biology — at roughly a fraction of a percent per year, his cumulative risk over five years does not justify ablation's costs and stricture risk, but it does justify protocolised re-inspection.
Two years later a report reads "focal low-grade dysplasia". Before acting, the slides are reviewed by an expert pathologist — regeneration mimics dysplasia, and overcalling low grade is a recognised problem. Confirmed, the flat segment undergoes radiofrequency ablation, eradicating the metaplasia and dropping progression risk substantially.
Now suppose the same segment harbours a 12 mm nodule: the nodule is not ablated — it is resected by endoscopic mucosal resection, because visible lesions may already harbour invasive disease, and the histology of that resected disc decides between continued endoscopic therapy and oesophagectomy.
Where students slip
The first error is the "fundoplication cures Barrett" reflex: surgery restores the antireflux barrier and resolves symptoms, but established metaplasia persists, and the examined answer is that surveillance continues after the operation. The second is biopsy technique — reporting "biopsies from the oesophagus: benign" without acknowledging the protocol; random nicks from the distal cm miss the very dysplasia surveillance exists to find, and the Seattle quadrants every 2 cm is the phrase that earns the mark. The third is ablation zeal in nondysplastic disease: at the population level the numbers favour surveillance, reserving ablation for confirmed dysplasia — a nuance examiners probe by asking "would you ablate a C2M3 segment with no dysplasia in a 40-year-old?" where the safe general answer is surveillance, with ablation discussed for select young patients with long segments.
Frequently asked questions
What histological finding establishes the diagnosis of Barrett oesophagus?
Intestinal metaplasia (goblet cells) in biopsies from a visibly columnar-lined distal oesophagus; columnar change without intestinal metaplasia does not qualify under most guidelines.
What is the Prague classification?
A C&M system documenting the circumferential (C) and maximal (M) extent of the columnar segment in centimetres from the top of the gastric folds to the squamocolumnar junction.
What is the Seattle biopsy protocol?
Four-quadrant biopsies at 2 cm intervals along the Barrett segment (1 cm intervals if dysplasia is known) plus targeted samples of visible lesions, processed separately by level.
How often is nondysplastic Barrett surveyed?
Every three to five years per current guidance, contingent on adequate protocol biopsies.
How is confirmed dysplasia managed?
Visible lesions undergo endoscopic mucosal resection for histology; flat low- or high-grade dysplasia is treated with radiofrequency ablation, followed by intensive surveillance until eradication.
Does antireflux surgery remove the cancer risk?
No — fundoplication controls reflux symptoms but does not reliably regress metaplasia or abolish progression, so surveillance endoscopy continues after the operation.